Senores Pharmaceuticals Limited has announced its un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results in a meeting held on January 20, 2026.

For the third quarter of FY26, the company reported a consolidated total income of ₹175 crore, a significant increase of 64% year-on-year. EBITDA stood at ₹54 crore, up 86%, and Profit After Tax (PAT) was ₹34 crore, a growth of 105% compared to the same period last year.

For the nine months ended December 31, 2025 (9M FY26), consolidated total income reached ₹474 crore, marking a 65% increase year-on-year. EBITDA for the period was ₹138 crore (up 87%), and PAT was ₹85 crore (up 110%).

The company highlighted strong performance in its Regulated Markets, with Q3 FY26 revenue at ₹112.7 crore (up 60.5% YoY) and an EBITDA margin of 40%. For 9M FY26, revenue was ₹309.6 crore (up 71.5% YoY) with an EBITDA margin of 40%.

In Emerging Markets, Q3 FY26 revenue was ₹38.4 crore, and for 9M FY26, it was ₹61 crore. The EBITDA margin for emerging markets improved significantly to 13% in Q3 FY26 from 1% in Q3 FY25, with margins at 13% and 9% for Q3 and 9M FY26 respectively.

Senores Pharmaceuticals has an approved portfolio of 46 ANDAs with 137 strengths in Regulated Markets, and 22 additional ANDAs under development with over 50 strengths. The company also has a CDMO/CMO portfolio with 16 products and 34 strengths commercialized.

Regarding the acquisition of Apnar Pharmaceuticals, Phase 1 (75% stake) is complete, with Phase 2 (balance 25%) expected by Q2 FY27. Three approved ANDAs from Apnar are slated for launch in Q4 FY26.

Swapnil Shah, Managing Director, stated that the company is on track to meet its full-year guidance, driven by expansion in the ANDA portfolio, scale-up of CDMO/CMO, profitability improvement in Emerging Markets, and scale-up of the Branded Generics business in India.